Alzheimer's research pinpoints antibodies that may prevent disease

Jul 06, 2009

Antibodies to a wide range of substances that can aggregate to form plaques, such as those found in Alzheimer's patients, have been identified in the blood and cerebrospinal fluid of healthy people. Levels of these antibodies decline with age and, in Alzheimer's patients, with increasing progression of the disease.

These findings by Stanford University School of Medicine researchers and outside collaborators, described in a paper to be published online July 6 in the journal , raise the possibility that many of us are carrying in our blood that could be playing a role in staving off or slowing the progression of Alzheimer's disease. This seems to be true even when we are young and healthy and would presumably have had little or no exposure to the substances that build up in the brain to cause this disorder.

Alzheimer's disease is characterized by the build-up of in the brain. These are large aggregations of a protein breakdown product, or peptide, called A-beta. Many experiments have shown that immunization with A-beta can reduce the formation of amyloid plaques. Clinical trials now underway are exploring whether this can safely produce cognitive benefits in Alzheimer's patients, while other trials are treating patients directly with antibodies to A-beta.

But A-beta is a slippery character. A number of different modified, mutated, or metabolized forms of this peptide may also be involved in the disease. Furthermore, it is believed that more than the plaques themselves (which are also found in the brains of people with no Alzheimer's symptoms), it is smaller aggregations of a few A-beta molecules, called oligomers, which are most toxic to neurons.

"Other studies have found antibodies against A-beta, but nobody has ever done a large-scale analysis using hundreds of different samples and almost a hundred different to look for what's already in people's bodies," said the paper's first author, Markus Britschgi, PhD, an instructor working as a researcher in the laboratory of Tony Wyss-Coray, PhD. Wyss-Coray, associate professor of neurology and neurological sciences, is the paper's senior author.

Britschgi, Wyss-Coray, and their colleagues used a microarray technology in which a large number of different peptides are affixed to pixels on a microchip, which signals binding of those peptides by antibodies. This technology was developed in a neighboring lab by another co-author of the paper, William Robinson, MD, assistant professor of rheumatology, and other Stanford scientists.

The investigators customized microarrays containing close to 100 different peptides apiece, including A-beta and several of its metabolized, modified, and mutant forms. The peptides were displayed in various degrees of aggregation, ranging from single molecules to small assemblages, or oligomers, to denser aggregates called fibrils. Also included on the chip were certain peptides whose constituent amino-acid sequences are unrelated to A-beta's but that are capable of aggregating to form other, rare plaque-associated dementias.

The researchers incubated these chips with blood samples from more than 250 individuals, who were between 21 and 89 years old, some with Alzheimer's disease and others without it. They observed antibodies targeting many forms and aggregation-states of A-beta in both healthy and diseased subjects' blood, with antibodies to oligomers showing the most immunoreactivity. They then showed that overall levels of these antibodies decline with age and, in those with Alzheimer's, with advancing stages of the disease.

"This was the first study to show an age-related decline in the levels of these antibodies," said Britschgi.

A follow-on experiment showed that the same antibodies, whether isolated from plasma of either Alzheimer's patients or healthy controls, were able to protect freshly cultured mouse neurons in a dish from destruction by A-beta, which is typically highly toxic to these neurons.

Furthermore, the researchers studied samples from vervet monkeys, who, like humans, develop A-beta-derived brain plaques as they age. Earlier experiments performed at another institution have shown that immunizing older monkeys with A-beta substantially cleared their plaques. In this new study, the Stanford team obtained blood samples extracted from those monkeys before and after immunization, and compared levels and diversity of relevant antibodies in pre- and post-inoculation samples. They observed several such antibodies in the pre-immunized samples, as well as significant post-immunization increases in levels of several different antibodies.

Interestingly, in both monkeys and healthy human subjects the investigators' microarrays also detected antibodies to a couple of mutated peptides associated with rare dementias which have brain plaques bearing a striking resemblance to those of Alzheimer's with a notable exception. Oddly, these dementia-related peptides' amino-acid sequences are nothing like that of A-beta's, yet antibodies against them occur even in the blood of healthy study subjects who have never been diagnosed with any of those rare dementias.

Wyss-Coray and Britschgi think this may mean that at least some of the antibodies they've isolated target not plaque-generating peptides' amino-acid sequences, but rather some common shape these assume in the early, oligomeric stages of their aggregation, when they are most toxic.

The methods the researchers used, for which Stanford has filed provisional patent applications, could lead to improved monitoring of clinical trials of immunotherapeutic treatments for Alzheimer's disease, Wyss-Coray said. "With our microarray, you could easily look for antibodies to hundreds of different peptides. It would be possible to see whether certain types of antibodies correlate better with cognitive benefits than others do."

Another possibility, said Wyss-Coray, is to try immunizing Alzheimer's patients with peptides that, unlike A-beta, have amino-acid sequences unlike any of those occurring naturally in the human body — but that, by virtue of their three-dimensional similarity to A-beta as they begin to aggregate, generate antibodies to A-beta oligomers as well. This would reduce the possibility of an autoimmune reaction to such a vaccine, which resulted in the halting of an otherwise promising clinical trial several years ago, he said.

Source: Stanford University Medical Center (news : web)

Explore further: US scientists make embryonic stem cells from adult skin

add to favorites email to friend print save as pdf

Related Stories

Potatoes may hold key to Alzheimer's treatment

Aug 15, 2008

A virus that commonly infects potatoes bears a striking resemblance to one of the key proteins implicated in Alzheimer's disease (AD), and researchers have used that to develop antibodies that may slow or prevent the onset ...

Study suggests blood test for Alzheimer's possible

Mar 11, 2009

Researchers have revealed a direct relationship between two specific antibodies and the severity of Alzheimer's disease symptoms, raising hopes that a diagnostic blood test for the devastating disorder is within reach.

Recommended for you

Leeches help save woman's ear after pit bull mauling

Apr 18, 2014

(HealthDay)—A pit bull attack in July 2013 left a 19-year-old woman with her left ear ripped from her head, leaving an open wound. After preserving the ear, the surgical team started with a reconnection ...

New pain relief targets discovered

Apr 17, 2014

Scientists have identified new pain relief targets that could be used to provide relief from chemotherapy-induced pain. BBSRC-funded researchers at King's College London made the discovery when researching ...

User comments : 0

More news stories

Less-schooled whites lose longevity, study finds

Barbara Gentry slowly shifts her heavy frame out of a chair and uses a walker to move the dozen feet to a chair not far from the pool table at the Buford Senior Center. Her hair is white and a cough sometimes interrupts her ...

How to keep your fitness goals on track

(HealthDay)—The New Year's resolutions many made to get fit have stalled by now. And one expert thinks that's because many people set their goals too high.

Low tolerance for pain? The reason may be in your genes

Researchers may have identified key genes linked to why some people have a higher tolerance for pain than others, according to a study released today that will be presented at the American Academy of Neurology's 66th Annual ...

Growing app industry has developers racing to keep up

Smartphone application developers say they are challenged by the glut of apps as well as the need to update their software to keep up with evolving phone technology, making creative pricing strategies essential to finding ...

Making graphene in your kitchen

Graphene has been touted as a wonder material—the world's thinnest substance, but super-strong. Now scientists say it is so easy to make you could produce some in your kitchen.